(NASDAQ: MNPR) Monopar Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Monopar Therapeutics's earnings in 2025 is -$16,570,165.On average, 5 Wall Street analysts forecast MNPR's earnings for 2025 to be -$11,496,602, with the lowest MNPR earnings forecast at -$15,471,491, and the highest MNPR earnings forecast at -$7,949,778. On average, 4 Wall Street analysts forecast MNPR's earnings for 2026 to be -$20,868,168, with the lowest MNPR earnings forecast at -$36,752,436, and the highest MNPR earnings forecast at -$10,273,560.
In 2027, MNPR is forecast to generate $4,036,041 in earnings, with the lowest earnings forecast at $3,669,128 and the highest earnings forecast at $4,402,954.